Indications of Epclusa

Sofosbuvir/Velpatasvir is a fixed-dose combination preparation containing sofosbuvir (an HCV nucleotide analog NS5B polymerase inhibitor) and velpatasvir (an HCV NS5A inhibitor). It is indicated for the treatment of adult and pediatric patients aged 3 years and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection, including: patients without cirrhosis or with compensated cirrhosis; and patients with decompensated cirrhosis, which requires combination use with ribavirin.

FDA，2022.04